NO20002697D0 - Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen - Google Patents

Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen

Info

Publication number
NO20002697D0
NO20002697D0 NO20002697A NO20002697A NO20002697D0 NO 20002697 D0 NO20002697 D0 NO 20002697D0 NO 20002697 A NO20002697 A NO 20002697A NO 20002697 A NO20002697 A NO 20002697A NO 20002697 D0 NO20002697 D0 NO 20002697D0
Authority
NO
Norway
Prior art keywords
diagnostic
variation
diseases caused
therapeutic preparation
lkb1 gene
Prior art date
Application number
NO20002697A
Other languages
English (en)
Other versions
NO20002697L (no
Inventor
Dieter E Jenne
Jun-Ichi Nezu
Original Assignee
Chugai Res Inst Molecular Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Res Inst Molecular Med filed Critical Chugai Res Inst Molecular Med
Publication of NO20002697D0 publication Critical patent/NO20002697D0/no
Publication of NO20002697L publication Critical patent/NO20002697L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20002697A 1997-11-27 2000-05-26 Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen NO20002697L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34425697 1997-11-27
JP28035798 1998-10-01
PCT/JP1998/005357 WO1999028459A1 (en) 1997-11-27 1998-11-27 Examination method, examination reagent and remedy for diseases caused by variation in lkb1 gene

Publications (2)

Publication Number Publication Date
NO20002697D0 true NO20002697D0 (no) 2000-05-26
NO20002697L NO20002697L (no) 2000-07-27

Family

ID=26553739

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002697A NO20002697L (no) 1997-11-27 2000-05-26 Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen

Country Status (6)

Country Link
US (1) US6800436B1 (no)
EP (1) EP1036844A4 (no)
AU (1) AU750564B2 (no)
CA (1) CA2311414A1 (no)
NO (1) NO20002697L (no)
WO (1) WO1999028459A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1186232A4 (en) 1999-05-31 2004-11-10 Chugai Pharmaceutical Co Ltd 'KNOCKOUT' ANIMALS LACKING THE LKB1 GENE
AU2001271067A1 (en) * 2000-07-19 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Method of screening compound controlling mek/erk signal transduction and medicinal use of the compound
DK1633883T3 (da) * 2003-06-17 2009-01-26 Medical Res Council Fremgangsmåde til analyse af LKB1-phosphoryleringsaktivitet
CN101072883B (zh) * 2004-12-08 2012-05-23 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
CA2611788A1 (en) * 2005-06-30 2007-01-11 Syngenta Participations Ag Methods for screening for gene specific hybridization polymorphisms (gshps) and their use in genetic mapping and marker development
BR112012019459A2 (pt) * 2010-02-03 2017-10-17 Signal Pharm Llc identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
TW201527300A (zh) 2013-04-17 2015-07-16 Signal Pharm Llc 關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－三唑－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法
WO2014172432A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
EA029072B1 (ru) 2013-04-17 2018-02-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты
JP6382949B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
MX2015014589A (es) 2013-04-17 2016-04-25 Signal Pharm Llc Tratamiento de cancer con dihidropirazino-pirazinas.
WO2014172426A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
BR112015026021A2 (pt) 2013-04-17 2017-07-25 Signal Pharm Llc terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
EP0816501B1 (en) * 1995-03-16 2005-06-01 Chugai Seiyaku Kabushiki Kaisha Dna encoding protein kinase
JPH08308586A (ja) * 1995-03-16 1996-11-26 Chugai Pharmaceut Co Ltd プロテインキナーゼをコードするｄｎａ

Also Published As

Publication number Publication date
CA2311414A1 (en) 1999-06-10
EP1036844A4 (en) 2002-12-04
WO1999028459A1 (en) 1999-06-10
AU750564B2 (en) 2002-07-25
AU1262099A (en) 1999-06-16
US6800436B1 (en) 2004-10-05
EP1036844A1 (en) 2000-09-20
NO20002697L (no) 2000-07-27

Similar Documents

Publication Publication Date Title
NO20002697D0 (no) Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen
ATE322269T1 (de) Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung
NO20016364D0 (no) Fremgangsmåte og anordning for noninvasiv blodanalysemåling
DE60313602D1 (de) N-iPHENYL(PIPERIDIN-2-YL)METHYLöBENZAMIDDERIVATE,VERFAHREN ZU IHRER HERSTELLUNG UND IHRE THERAPEUTISCHE ANWENDUNG
DE60239669D1 (de) Sojabohnenprotein, verfahren zu seiner herstellung sowie dessen säure enthaltende proteinnahrungsmittel
NO974521L (no) Preparat for grunning av dentale og biologiske substrater
NO20012689D0 (no) Nye fluider og teknikker for matriks syrebehandling
DK0739898T3 (da) Phosphononmoneosternukleinsyrer, fremgangsmåde til fremstilling deraf og anvendelse deraf
DE60336264D1 (de) Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel sowie zwischenprodukte und methoden zu ihrer herstellung
ATE242762T1 (de) Acrylonitril-derivate, verfahren zu ihrer herstellung und diese enthaltende schädlingsbekämpfungsmittel
IS5852A (is) Lyfjamiðlar til meðhöndlunar á parkinsonsveiki ADHD og smákirtilsæxlum
ATE267202T1 (de) 1,4-diazabicyclo(3.2.2)nonanbenzoxazol-, benzothiazol- und benzoimidazolderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
NO961000D0 (no) Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike
ATE290366T1 (de) Pharmazeutische formulierung mit überdecktem geschmack und verfahren zu ihrer herstellung
AU2002332102A1 (en) System, method, and apparatus for disease susceptibility testing
AU6225999A (en) Disposable training pant, apparatus and method for manufacturing it
AU2002239664A1 (en) Method for drug development using individual patient response
WO2002063951A3 (en) Human disease modeling using somatic gene transfer
DE60003662D1 (de) Pyridothienodiazepine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
AU2000279747A1 (en) Emulsion of perfluororganic compounds for medical purposes, method for producingsaid emulsion and methods for curing and preventing diseases with the aid of the emulsion
ATE294181T1 (de) (3,4-a:3,4-c)carbazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
AU2003276727A1 (en) Method of haplotype-based genetic analysis for determining risk for developing insulin resistance, coronary artery disease and other phenotypes
AU2003284166A1 (en) Methods for diagnosing and treating pre-term labor
DE59911949D1 (de) Substituierte sulfonylcyanamide, verfahren zu ihrer herstellung und ihre verwendung als medikament
DE69516534D1 (de) Antikörper gegen allogene und xenogene proteine, ihre verwendung in diagnose und therapie und verfahren zu ihrer bestimmung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application